The SiPore21 device, if cleared, will be registered as a Class IIb medical device. Image Credit: Mikhailava Alesia / Shutterstock.

Sigrid Therapeutics has started the Shine clinical trial for SiPore21, a device designed to control diabetes and obesity.

SiPore technology is based on mesoporous silica particles (MSPs), a colloidal amorphous silicon dioxide matrix. It acts like a “molecular sieve” to physically prevent the interaction between digestive enzymes and food, thereby reducing food breakdown into basic absorbable units. The SiPore21 device, if cleared, will be registered as a Class IIb medical device.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Most diabetes control devices are either continuous glucose monitors or insulin pumps. The market for these devices is forecasted to be worth around $20.8bn in 2033, as per GlobalData. With such a huge diabetes device market, many companies have alternative means to manage/control diabetes, such as information apps to increase disease awareness and scheduling apps to remind people about their medications.

GlobalData is the parent company of Clinical Trials Arena.

The placebo-controlled Shine trial will evaluate the safety and efficacy of SiPore21 in people with elevated blood glucose levels who are either obese or overweight.

The primary endpoint for the trial is lowering of the blood sugar, measured using haemoglobin A1c (HbA1c), compared with the placebo. The study’s secondary endpoints measure a wide range of health parameters such as body weight, insulin resistance and others.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial expects to enrol around 288 patients aged between 18 and 70 across three European countries. The recruitment is expected to be completed in H1 2024, with preliminary data expected in Q2 2024.

In January, Sigrid raised SKr10.6m ($0.96m) to fund the commercialisation of the previous version of the SiPore device, SiPore15. The company is seeking a market registration in the EU for the diabetes control device.